A discovery is making its way in the field of medicine and could have significant implications for those who are fighting the Parkinson.
A recent study, published in The New England Journal of Medicine, reveals that a medication originally designed to treat diabetes, the lixisenatid, could also slow down the progression of Parkinson's symptoms.
The study focused on patients in the initial stages of the disease, who were administered lixisenatid for 12 months.The results were encouraging: those treated with lixisenatida maintained their stable motor capabilities, compared to an observable deterioration in the group that received a placebo.
What does this mean?According to experts, the agonists of the GLP-1 receiver, such as the leveling, not only act in the intestine to regulate blood sugar, but also have neuroprotective effects on the brain.
These drugs protect dopaminergic neurons, which are crucial for motor control and are progressively destroyed by Parkinson's.
This research is particularly exciting because it opens a new way to understand and potentially treat not only Parkinson's, but also other neurodegenerative diseases such as Alzheimer's.
Insulin receptors, who play a vital role in our brain functions, seem to have a connection with insulin resistance observed in these diseases.
On the other hand, scientists also underline the importance of maintaining healthy lifestyles, especially physical activity, which has shown to protect neuronal functions.
This finding is a reminder of how medical research can offer unexpected hope and solutions, crossing the lines between different medical conditions to find common solutions.
As we continue to explore these links, we can find more effective ways to treat or even prevent diseases that affect millions of people worldwide.
Let's continue aware of these advances!
Greetings,
